DiaMedica Therapeutics Inc.
Developing a novel protein therapy for acute ischemic stroke and preeclampsia.
DMAC | US
Overview
Corporate Details
- ISIN(s):
- CA25253X2077
- LEI:
- Country:
- United States of America
- Address:
- 301 CARLSON PARKWAY, 55305 MINNEAPOLIS
- Website:
- https://www.diamedica.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for diseases with significant unmet medical needs. The company's lead drug candidate, DM199, is a recombinant form of the human protein tissue kallikrein-1 (rhKLK1). It is being developed as a protein replacement therapy intended to restore normal KLK1 levels to improve blood flow and reduce inflammation. The primary focus areas for DM199 are the treatment of acute ischemic stroke (AIS) and preeclampsia, addressing critical gaps in patient care for these conditions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all DiaMedica Therapeutics Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for DiaMedica Therapeutics Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for DiaMedica Therapeutics Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
/other/Diamyd_Medical_AB_publ-logo.png){kind=logo}
